Investing.com – Pfizer stock (NYSE:) gained nearly 4% in Tuesday’s premarket trading as higher revenue from its vaccine against Covid-19 led the company to raise its guidance for the year.

At the midpoint in its forecast range, Comirnaty’s Covid-19 vaccine sales are expected to reach $81.5 billion. It’s $2.5billion more than was forecasted. The non-Covid vaccin business, however, is seen as a fraction of the previous forecast. Sales at the midpoint were $45.5 billion. This represents a decrease from the $46 billion that was projected.

Third-quarter group sales at $24.1 billion were 130% greater than last year, thanks to increasing vaccines for pandemics all over the globe. The adjusted profit per share, which was $1.34 was higher than expected.

Covid-19 vaccines’ revenue is 2.3 billion. This figure represents an increase of 2.1 billion in the number of doses that were tied up previously. Covid’s sales were forecasted at $33.5 billion by the company.

In the end, the outlook suffered from the quality issue that led to the recall of Chantix tablets. Since then, the company has stopped shipping this product. Chantix can be used for short-term relief of smoking problems. The medication contained an inacceptably high amount of a carcinogen, according to tests.